Full Press Release Details
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA.
IMMP
Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
Key Takeaway: Immutep’s LAG-3 Immunostimulant Product Candidate, Efti, Receives IND Approval from U.S. FDA
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)